{"id":"W4405050900","doi":"10.1016/j.esmoop.2024.104073","title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Renal cell carcinoma; Open label; Internal medicine; Oncology; Randomized controlled trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003045645,0.001242552,0.001782346,0.0002222393,0.0002665378,0.001094763,0.0009468952,0.00103785,0.003024435],"category_scores_gemma":[0.001692398,0.0003668299,0.00202772,0.0003175012,0.0005865599,0.0009761964,0.0004750852,0.001988427,0.0005666823],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00129742,"about_ca_system_score_gemma":0.001325515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001423213,"about_ca_topic_score_gemma":0.003279323,"domain_scores_codex":[0.9991969,0.000407749,0.00004962968,0.0001531565,0.00006609858,0.0001264209],"domain_scores_gemma":[0.9986742,0.0002362222,0.0004479816,0.0001155432,0.00008241815,0.0004436995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9540657,0.007243271,0.003892368,0.0006301996,0.001916314,0.00003646613,0.00009977193,0.001081723,0.00274393,0.000105132,0.001755814,0.02642929],"study_design_scores_gemma":[0.8888854,0.09746541,0.009582769,0.00005256766,0.00115104,0.0001066208,0.00004088904,0.0005851667,0.0004566857,0.000126726,0.001524574,0.00002208512],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911082,0.004581989,0.0002296653,0.0003807888,0.0001688052,0.00111912,0.001253401,0.00004512877,0.001113011],"genre_scores_gemma":[0.9907802,0.001834138,0.0008799831,0.0007248069,0.0002877583,0.00117569,0.00311669,0.00001930495,0.001181422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003045645,"threshold_uncertainty_score":0.01610714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03543818598914407,"score_gpt":0.3104221155019698,"score_spread":0.2749839295128257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}